| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2006PNAS..10316930K |
| P356 | DOI | 10.1073/PNAS.0604902103 |
| P932 | PMC publication ID | 1629449 |
| P698 | PubMed publication ID | 17077140 |
| P5875 | ResearchGate publication ID | 6719696 |
| P50 | author | John Dick | Q6229356 |
| Jeremy A. Squire | Q39802515 | ||
| P2093 | author name string | D L Barber | |
| J A Kennedy | |||
| J Bayani | |||
| F Barabé | |||
| B J Patterson | |||
| P2860 | cites work | The Janus kinases (Jaks) | Q21194856 |
| Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells | Q24669651 | ||
| Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo | Q28210990 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 | Q28243103 | ||
| Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 | ||
| A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 | ||
| PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation | Q28263004 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes | Q33889476 | ||
| Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells | Q34063522 | ||
| Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | Q34245259 | ||
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia | Q36185370 | ||
| Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation | Q36402468 | ||
| TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways | Q40714424 | ||
| TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway | Q40795252 | ||
| Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells | Q40895260 | ||
| Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling | Q40949830 | ||
| Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming | Q43966206 | ||
| Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells | Q44471784 | ||
| Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. | Q44854570 | ||
| AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation | Q45204173 | ||
| BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice | Q45240581 | ||
| Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. | Q45869160 | ||
| Distinct classes of human stem cells that differ in proliferative and self-renewal potential | Q45873643 | ||
| The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene | Q46643222 | ||
| Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case | Q46753958 | ||
| Letter: Bone-marrow responses in polycythemia vera | Q47871256 | ||
| Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation. | Q53630624 | ||
| Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2 | Q57054898 | ||
| Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells | Q59599864 | ||
| Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice | Q75312804 | ||
| Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice | Q78410479 | ||
| A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma | Q82314612 | ||
| Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells | Q83310312 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| myelofibrosis | Q1752571 | ||
| P304 | page(s) | 16930-16935 | |
| P577 | publication date | 2006-10-31 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo | |
| P478 | volume | 103 |
| Q36079807 | Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments |
| Q38598868 | Cytokine Signaling in Tumor Progression |
| Q38999178 | Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts |
| Q37237331 | Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia |
| Q36285745 | JAK Kinases in Health and Disease: An Update |
| Q33378737 | JAK and MPL mutations in myeloid malignancies |
| Q34641224 | JAK/STAT signaling in hematological malignancies. |
| Q21285040 | JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms |
| Q24322021 | Janus kinases in immune cell signaling |
| Q37379320 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. |
| Q33753094 | Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis |
| Q54633559 | Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes |
| Q42133453 | Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells |
Search more.